secwatch.observer — SEC 8-K summary
======================================

Issuer:     Eloxx Pharmaceuticals, Inc. (ELOX)
CIK:        0001035354
Form:       8-K
Filed at:   2021-09-30T23:59:59+00:00
Accession:  0001104659-21-121017
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Eloxx enters $50M at-the-market equity distribution agreement with SVB Leerink
------------------------------------------------------------------------------

- Up to $50M in common stock may be sold through SVB Leerink as sales agent under ATM program.
- SVB Leerink receives 3% commission on gross sales proceeds; company provides customary indemnification.
- Shares sold pursuant to existing S-3 shelf registration and prospectus supplement dated Sept 30, 2021.
- Company is not obligated to sell any shares; agreement can be terminated by either party at any time.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1035354/000110465921121017/0001104659-21-121017-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1035354/000110465921121017/tm2128746d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-21-121017

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer